CYCC Stock Price, Chart, Stats & News
Cyclacel Pharmaceuticals, Inc. (CYCC) is a dividend-paying stock. It distributes annually.
CYCC chart
Price history is unavailable
We don't have enough price data for CYCC to draw a chart yet.
Fundamentals
Gross margin | 114.50% |
Operating margin | 23431.35% |
Pretax margin | 9324.40% |
Net margin | 12749.47% |
Effective tax rate | -36.73% |
ROA | -54572.05% |
ROE | -393.45% |
D/E | – |
Interest coverage ratio | -909110.22x |
CYCC valuation
P/E | – |
P/S | -303.80x |
P/B | 1715.48x |
P/CF | 4.14x |
P/FCF | 3.61x |
P/OCF | 4.14x |
PEG | 0.68x |
EV multiple | -1.29x |
About
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies.
Related lists
Similar securities
Based on sector and market capitalization
